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Although the success of trastuzumab and rituximab for treat-
ment of breast cancer and non-Hodgkins lymphoma, re-
spectively, suggests that monoclonal antibodies (mAbs) will 
become important therapeutic agents against a wider range 
of cancers, useful therapeutic Abs are not yet available for 
the majority of the human cancers because of our lack of 
knowledge of which antigens (Ags) are likely to become use-
ful targets. We established a procedure for comprehensive 
identification of such Ags through the extensive isolation of 
human mAbs that may be therapeutic. Using the phage-dis-
play Ab library we isolated a large number of human mAbs 
that bind to the surface of tumor cells. They were individually 
screened by immunostaining, and clones that preferentially 
and strongly stained the malignant cells were chosen. The 
Ags recognized by those clones were isolated by im-
munoprecipitation and identified by mass spectrometry 
(MS). We isolated 2,114 mAbs with unique sequences and 
identified 25 distinct Ags highly expressed on several 
carcinomas. Of those 2,114 mAbs 434 bound to specifically 
to one of the 25 Ags. I am going to discuss how we could se-
lect proper target Ags for therapeutic Abs and candidate 
clones as therapeutic agents. [Immune Network 2009;9(1): 
4-7]
INTRODUCTION
In order to develop therapeutic mAbs against cancers, many 
groups  have  been  trying  to  identify  tumor-associated  Ags 
(TAAs) using micro array technology (1,2). Afterwards they 
started to generate mAbs against them. Our approach was de-
signed  in  the  opposite  way  to  this  strategy  and  is  quite 
straightforward. At the first step we isolated a large number 
of  human  mAbs  that  bound  to  membrane  proteins  present 
on cancer cells. At the second step we selected clones that 
significantly and selectively bound only to tumor cells. At the 
third step we identified Ags that were recognized by such tu-
mor-specific Abs. Finally we searched for clones that showed 
strong anti tumor activities in vitro and in vivo. If this strategy 
can  work  well,  many  researchers  in  this  field  will  adopt  it 
and do it. However, when we performed experiments in a 
conventional way, we experienced a couple of problems. In 
the  first  process  the  number  of  clones  with  different  se-
quences in the pool of mAbs picked up tended to be limited. 
Moreover, the affinity of isolated clones to the Ags was not 
so high as expected. In the third process it has not been easy 
to comprehensively identify the Ags recognized by respective 
mAbs because they are membrane proteins. Actually a couple 
of groups adopted a similar strategy to ours, but they identi-
fied  only  few  TAAs  (3,4). 
IDENTIFICATION OF TAAs AND SIMULTANEOUS 
ISOLATION OF HUMAN mAbs AGAINST THEM
One of the main issues to be solved was development of a 
screening method for comprehensive isolation of mAbs spe-
cific against membrane proteins. As a source of Abs we used 
a phage Ab library constructed from human B lymphocytes 
(5)  .  In  the  case  of  conventional  method  (6,7),  cells  and 
phage particles are mixed. After Ags and Abs form complexes 
on the cell surface, the cells are collected by centrifugation. 
Since the complex formation is an equilibrium reaction, we Human mAbs Against TAAs
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could expect that the Abs with strong affinity to Ags should 
stay  with  cells  longer  than  the  Abs  with  weak  affinity. 
However,  majority  of  the  clones  isolated  by  this  method 
showed  low  affinity  and  appeared  to  be  biased  to  specific 
clones.  When  the  researchers  obtained  these  results,  they 
usually thought that since the Abs contained in the Ab library 
are naive to the Ags, they could not expect the Ab with high 
affinity to the Ags. We also thought so in the beginning, but 
gradually started to understand well the characteristics of the 
phage  Ab  system.  Finally  we  succeeded  in  developing  the 
ICOS (isolation of Ag/Ab complexes through organic solvent) 
method (8). In the case of the ICOS method while the first 
step  for  mixing  of  the  cells  and  phage  Abs  in  an  aqueous 
solution is the same as that in the conventional method, the 
mixture is put on the organic layer and centrifuged. Therefore 
the phages complexed with cells via Ag/Ab interaction were 
collected through organic solution. Majority of the clones iso-
lated by the ICOS method showed good quality in terms of 
diversity  and  affinity.  We  performed  51  time  screenings 
a g a i n s t  3 3  d i f f e r e n t  c a n c e r  c e l l  l i n e s  d e r i v e d  f r o m  h e p -
atocarcinoma,  renal  carcinoma,  pancreatic  carcinoma,  lung 
carcinoma, colonic cancer, gastric cancer and ovarian cancer. 
We picked up around 200 clones on average in each screen-
ing,  therefore,  9,395  clones  in  total.  Among  them  80%  of 
clones  expressed  the  Ab  on  the  phage  particle.  Sequence 
analysis  indicated  the  same  clones  had  been  redundantly 
isolated. Therefore, finally 2,114 distinct clones were isolated 
in  these  screenings  (9). 
    At the second step we extensively carried out immunohi-
stochemical analyses using fresh cancer tissues for all of the 
2,114 mAbs isolated as above. The results indicated that ap-
proximately one third of the Abs isolated by the ICOS method 
bound  to  TAAs.  Although  these  observations  were  striking, 
that is, the frequency of tumor-specific staining appeared to 
be very high, much higher than we had expected, we initially 
doubted whether apparently TAAs are really tumor-specific or 
some artifacts or misjudgment. Eventually, these results turned 
o u t  t o  r e f l e c t  t h e  t r u e  s i t u a t i o n s .
    Since we had mAbs and the cells which expressed the tar-
get Ags recognized by respective clones, we imagined, in the 
b e g i n n i n g ,  t h a t  i t  m a y  b e  e a s y  f o r  u s  t o  i d e n t i f y  t h e  A g s  
one-by-one through purification either by imunoprecipitation 
or by affinity chromatography followed by MS. But soon it 
turned out to be not easy. The difficulty was mainly caused 
during  the  process  of  solubilization  by  detergent.  Further-
more, we had several hundred mAbs. If we had to identify 
Ags  one-by-one,  it  looked  an  endless  work.  In  our  system 
a single-chain Fv (scFv)-CL form fused with a truncated cp3 
was adopted as the phage-display Ab form. In this molecular 
form, it will take a long time for us to purify many clones 
such  as  several  hundreds.  But  since  in  our  gene  form  an 
scFv-CL-cp3 can be easily converted to an scFv-CL fused with 
protein A domains simply by digestion with a restriction en-
zyme followed by ligation (10). Therefore, we easily purified 
many clones by using IgG-conjugate column, and then they 
were used for further analysis. In order to comprehensively 
identify the Ags recognized by many clones, we newly devel-
oped  two  methods,  GFC  [grouping  of  clones  by  flow  cy-
tometry (FCM)] method and SITE [simultaneous identification 
of  clones  through  three  dimensional  ELISA  (enzyme-linked 
immunosorbent  assay)]  method. 
    When we looked at the patterns analyzed by FCM using 
various mAbs against some specific cells and compared them, 
we noticed that some of the patterns recognized by different 
clones were almost identical to each other. It is likely that 
they recognized the same molecules or the same complexes. 
W e  r o u t i n e l y  p e r f o r m e d  F C M  a n a l y s i s  o f  r e s p e c t i v e  m A b s  
against six different cells. Based on the similarity of the pat-
terns, the clones were classified into groups and presence of 
30  to  40  groups  were  revealed.  We  termed  this  procedure 
the GFC method. The clones classified into the same group 
were  simultaneously  treated  for  immunoprecipitation  fol-
lowed by MS. Since Ab quite often showed a cross-reactivity, 
moreover since amounts of membrane protein were generally 
much smaller than those of cytoplasmic proteins, it is not easy 
to purify by only one immunoprecipitation. Contaminated cy-
toplasmic proteins disturbed the MS analyses. Therefore, we 
biotinylated membrane proteins before immunoprecipitation. 
By these devices we have succeeded in identification of 25 
kinds of TAAs as summarized in Table I (9). They were rec-
ognized  by  91  mAbs.  But  we  have  several  hundred  more 
clones  that  gave  cancer-specific  staining  patterns. 
We had 2,114 mAbs with different sequences. While 91 of 
t h e m  w e r e  k n o w n  t o  b i n d  t o  o n e  o f  t h e  a b o v e  2 5  A g s ,  i t  
was  quite  likely  that  there  remained  many  clones  that  also 
bound  to  one  of  them.  Therefore,  we  prepared  the  poly-
peptides  that  corresponded  to  the  extracellular  portion  of 
these TAAs. If we performed ELISA against the 2,114 clones 
by using these polypeptides as Ags, we could know which 
clones bind to one of them. But ELISA of 2,114 samples re-
quired too much amount of Ags. Therefore we developed the 
S IT E m et h od .  Al l th e  cl on e s we re  st o re d in  9 6- w el l pla te s. Human mAbs Against TAAs
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Table I. Summary of TAAs identified to date
Ag MS
a ELISA
b
EGFR 3 6
HER2 1 　15
HGFR 3 　81
PTK7/CCK-4 1 　ND
PTP-LAR 5 　32
IGSF4 10 　13
ALCAM 3 6
ICAM-1 5 　17
Lu/BCAM 1 　46
CEACAM6 1 　ND
CD44 3 　10
EpCAM 2 1
CD9 1 　ND
Ecto-5’-nucleotidase  1 　ND
MCP 9 　78
EMMPRIN 1 0
TfR 6 1
CDCP1 2 　17
α3β11 4 　ND
αvβ37 　ND
α6β45 　ND
α2β11 　ND
PTGFRN 3 　ND
EphA2 1 　20
MHC-class I 2 　ND
Total 91 343
aNumber indicates that of different clones identified by MS 
analysis.
bClones identified by MS analysis are not included.
Table II. Classification of TAAs for development of therapeutic 
Abs
Category 1 Ags against which therapeutic Abs have already
been developed (EGFR, HER2, EpCAM).
Category 2 Ags which are well expressed in cancer cells 
and not in normal cells but which are not 
thought yet to be targets for therapeutic Abs 
since their function in carcinogenesis is not 
well known.
Category 3 Ags which are well expressed in cancer cells but
are also expressed in some normal organs, 
therefore, which are not though to be targets 
for therapeutic Abs.
T h e n  c l o n e s  w e r e  m i x e d  i n  t h ree  different  ways  according 
to plate number, column number and rank number. We per-
formed ELSA of much smaller number of mixed samples than 
2,114  each  of  which  was  composed  of  several  ten  clones. 
Based on the address numbers of mixtures, plate, column and 
rank  numbers,  that  gave  positive  signals,  we  could  know 
which clones were positive ones. Development of the SITE 
method enabled us to know that further 343 clones bind to 
one  of  the  25  TAAs  as  indicated  in  Table  I  (9).
REQUIREMENTS FOR THERAPEUTIC TARGET Ags 
AND Abs 
People suspected that since the Abs in the library should be 
naive to the TAAs, their affinity to the Ags may not be high 
enough for the therapeutic purpose. Therefore, after identi-
fication of new target Ags, they have to start isolating mAbs 
against them. They also argued that since we started mRNA 
of B cells present in human bodies as a source of immuno-
globulin genes for the construction of Ab library, Abs in the 
library  cannot  bind  well  to  the  human-originated  proteins. 
According  to  our  experiences,  however,  both  arguments 
turned out to be wrong. We succeeded in isolation of many 
kinds of mAbs with high affinity against almost any human- 
originated TAAs from human B cell-derived Ab library. Com-
parison  of  the  binding  activity  of  anti  EGFR  mAb  between 
commercially  ERBITUX  and  our  clones  indicated  that  both 
Abs had almost identical Ag binding activity to EGFR present 
on the living cell surface, such as 0.1 to 1 nM Kd value. We 
also  examined  the  accumulation  of  indium-111  labeled  anti 
EGFR Ab to the tumors in nude mice. Our mAb accumulated 
well to the cancer cells and the degree of accumulation was 
j u d g e d  t o  b e  a  s i m i l a r  l e v e l  t o  E r b i t u x .  T h e  A b - d e p e n d e n t  
cell-mediated  cytotoxicity  (ADCC)  activity  shown  by  anti 
EpCAM Ab was shown even at lower than picomolar level. 
These examples were not exceptional among the several hun-
dred clones that we have isolated. Therefore, the questions 
that remain to solve for development of therapeutic Abs are 
how to select TAAs as targets and how to select mAbs for 
performing  clinical  examinations.   
For  development  of  therapeutic  Abs  against  cancers,  we 
classified the Ags to three categories as summarized in Table 
II. Against the Ags such as EGFR, HER2 and EpCAM, ther-
apeutic Abs have already been developed. In these cases, it 
has  been  already  proved  that  mAbs  are  effective  against 
cancers.  There  are  only  a  few  Ags  among  the  25  Ags  that 
were classified into this category. One third of the Ags identi-
fied  to  date  were  classified  into  the  second  category. 
Although cancer-specific expression was very clear, they have 
not been considered to be proper targets for therapeutic Abs. Human mAbs Against TAAs
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In the case of Ags classified into this category their function 
in tumorigenesis has not been well charcterized. For exam-
ple, CD73 is an enzyme that mediates as nucleotidase from 
AMP to adenosine. We obtained the data that anti CD73 Ab 
completely inhibited cell growth. It is very difficult for us to 
imagine why the change from AMP to adenosine in the envi-
ronment of cancer cells is required for growth of cancer cells. 
Two thirds of the Ags were classified into category 3. Since 
these molecules are well expressed in cancer cells, we could 
consider  that  they  are  TAAs.  However,  they  are  also  ex-
pressed  in  some  normal  cells. 
In the case of mAbs that bound to the Ag classified into 
category 1, we have to find differences in anti tumor activity 
between  already  established  therapeutic  Abs  and  our  Abs. 
E v e n  t h e  A b s  e s t a b l i s h e d  a g a i n s t  s o m e  c a n c e r  a r e  e f f e c t i v e 
only to a part of the cancers. Since we isolated nine kinds 
o f  a n t i  E G F R  m A b s ,  w e  e x a m i n e d  t h e i r  in  vivo a n t i  t u m o r 
activity. ERBITUX showed strong anti tumor activity against 
A431 as well as ACHN in nude mice but did not show anti 
tumor activity against CCF-RC1 or HT-29. On the other hand, 
our mAb 048-006 showed strong anti tumor activity against 
a l l  o f  t h e  f o u r  k i n d s .  S i n c e  w e  h a v e  a l r e a d y  s h o w e d  t h a t  
048-006 and Erbitux bound to a functionally similar epitope 
(9), we wonder the orientation of complex formation could 
be  an  important  factor  for  anti  tumor  activity.
In the case of mAbs that bound to the Ag classified into 
category 2, it seems to be clear for us what we should do. 
After we examine the ordinary assay for anti tumor activity 
in vitro and in vivo, we are going to judge whether clinical 
examination  could  be  started  or  not.
Although ordinary researchers are not interested in the Ags 
classified  into  category  3  as  therapeutic  targets,  we  think 
these  TAAs  could  be  also  attractive  targets  for  therapeutic 
Abs. We have various kinds of mAbs against respective Ags. 
We  comprehensively  performed  immunostainings  against 
many  fresh  cancer  tissues  using  multiple  mAbs  that  bound 
to  the  same  Ag.  We  found  several  examples  showing  tu-
mor-specific  staining  patterns  by  some  specific  clone  while 
both tumor cells and normal cell were equally stained by the 
other clones. This suggested presence of the tumor-specific 
epitope different from the epitopes present on both normal 
and tumor cells that could be distinguished by mAbs. Thus, 
w e  b e l i e v e  t h a t  s o m e  o f  t h e  A g s  c l a s s i f i e d  i n t o  c a t e g o r y  3  
could  also  become  proper  targets  for  therapeutic  mAbs.
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